Somewhat Favorable Press Coverage Somewhat Unlikely to Impact DBV Technologies (DBVT) Share Price
Media coverage about DBV Technologies (NASDAQ:DBVT) has been trending somewhat positive on Monday, Accern reports. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. DBV Technologies earned a news impact score of 0.12 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.461845953027 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of equities research analysts have commented on DBVT shares. Jefferies Group LLC reissued a “buy” rating and issued a $47.00 price objective on shares of DBV Technologies in a research report on Thursday, June 1st. BidaskClub downgraded shares of DBV Technologies from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 14th. Deutsche Bank AG started coverage on shares of DBV Technologies in a research report on Friday, June 23rd. They issued a “buy” rating and a $46.00 target price on the stock. ValuEngine raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of DBV Technologies in a research report on Thursday, July 6th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $50.00.
Shares of DBV Technologies (NASDAQ DBVT) opened at 43.81 on Monday. The stock’s 50 day moving average is $44.12 and its 200-day moving average is $37.46. The stock’s market capitalization is $2.02 billion. DBV Technologies has a one year low of $31.87 and a one year high of $46.33.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact DBV Technologies (DBVT) Share Price” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/11/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-dbv-technologies-dbvt-share-price.html.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Stock Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related stocks with our FREE daily email newsletter.